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The earliest blood vessels in the mammalian embryo are formed when endothelial cells 14 
(ECs) differentiate from angioblasts and coalesce into tubular networks. Thereafter, the 15 
endothelium is thought to expand solely by proliferation of pre-existing ECs. Here we show 16 
that the earliest precursors of erythrocytes, megakaryocytes and macrophages, the yolk 17 
sac-derived erythro-myeloid progenitors (EMPs), provide a complementary source of ECs 18 
that are recruited into pre-existing vasculature. Whereas a first wave of yolk sac-resident 19 
EMPs contributes ECs to the yolk sac endothelium, a second wave of EMPs colonises the 20 
embryo and contributes ECs to intraembryonic endothelium in multiple organs, where they 21 
persist into adulthood. By demonstrating that EMPs constitute a hitherto unrecognised and 22 
non-redundant source of ECs, we reveal that embryonic blood vascular endothelium 23 
expands in a dual mechanism that involves both the proliferation of pre-existing ECs and 24 
the incorporation of ECs derived from hematopoietic precursors.  25 
Blood vessels distribute oxygen, nutrients, hormones and immune cells through the vertebrate 26 
body and help remove waste molecules. Accordingly, functional blood vessel formation during 27 
embryogenesis is a prerequisite for vertebrate life. Endothelial cells (ECs) form the inner lining of 28 
blood vessels to contain the blood and its constituents. In addition, ECs serve as signalling hubs to 29 
integrate tissue-derived and blood-borne signals to regulate vascular function. In the mammalian 30 
embryo, the first ECs arise from mesenchymal precursors termed angioblasts that condense into 31 
yolk sac vasculature and the paired dorsal aortae; this process is initiated on embryonic day (E) 32 
7.0 in mice 1. Subsequently, embryonic blood vascular endothelium is thought to expand in a 33 
process termed angiogenesis, in which ECs proliferate within existing endothelium to increase 34 
vascular diameter, extend sprouts into avascular tissue areas or remodel into smaller vessels by 35 
intussusceptive growth 1. Current consensus is therefore that embryonic ECs are a self-contained 36 
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cell lineage that expands by proliferation without contribution from new angioblasts or circulating 37 
precursors. In contrast, circulating endothelial progenitors and their relationship to monocytes and 38 
macrophages have controversially been described in adults 2. 39 
Monocytes and macrophages are mononuclear phagocytic cells of the innate immune system that 40 
also modulate vascular growth 3.  Thus, tissue-resident macrophages of the embryonic mouse 41 
central nervous system (CNS), termed microglia, and macrophages in the zebrafish larval trunk 42 
contact ECs at the tip of neighbouring vessel sprouts to promote their anastomosis into perfused 43 
vessel loops 4, 5. Microglia have similar roles in the injured adult zebrafish brain 6. Macrophages 44 
also secrete VEGFA to stimulate vessel growth for nerve repair in adult mice 7. In contrast, a direct 45 
contribution of macrophages or other myeloid cell (MC) types to embryonic vascular endothelium 46 
has not been reported; thus, CRE recombinase expression under the control of the myeloid Lysm 47 
or Vav promoters does not mark embryonic blood vascular endothelium in mice 8, 9.  48 
Most tissue-resident macrophages arise from erythro-myeloid progenitors (EMPs) that form in the 49 
extra-embryonic yolk sac during embryogenesis and also serve as precursors for erythrocytes and 50 
megakaryocytes 10-14. In mice, a wave of early EMPs, also referred to as primitive progenitors, 51 
buds from yolk sac blood islands between E7.0 and E8.25 and by E9.0 differentiates into yolk sac 52 
macrophages without monocytic intermediates 10, 13, 15-17. Early yolk sac macrophages also 53 
generate tissue-resident macrophages in the embryo proper, including microglia in the brain or 54 
Langerhans cells and Kupffer cells in the epidermis and liver, respectively 16. A later wave of EMPs 55 
buds from yolk sac endothelium from E8.25 onwards 10, 11, 14, 17. These cells leave the yolk sac via 56 
the circulation to colonise the liver 14, 18, where they expand into monocytes that subsequently 57 
colonise peripheral organs to differentiate into tissue-resident macrophages, thereby diluting the 58 
pool of early EMP-derived macrophages in many organs but not the CNS 10, 16.  59 
 60 
Lineage tracing with Csf1r-iCre identifies ECs in developing brain vasculature 61 
To target early EMPs 10, 13, 15, microglia 19, 20 and other differentiated MCs 21, we and others have 62 
used a transgene that expresses CRE recombinase under the control of the promoter for the 63 
myeloid lineage gene Csf1r (Fms), which encodes the colony-stimulating factor 1 receptor CSF1R. 64 
Microglia appear as amoeboid or ramified single YFP+ cells in hindbrains from mouse embryos 65 
carrying Csf1r-iCre and the RosaYfp CRE/LoxP recombination reporter, with microglia and ECs also 66 
stained for isolectin B4 (IB4) (Fig. 1a) 19. As previously shown 4, the number of IB4+ YFP+ microglia 67 
in the hindbrain subventricular zone increased between E10.5 and E11.5, when vessels fuse into 68 
the subventricular vascular plexus (SVP), and decreased after SVP formation by E12.5, when they 69 
move into deeper hindbrain layers (Fig. 1b). Surprisingly, Csf1r-iCre additionally targeted sporadic 70 
elongated IB4+ cells that appeared bound into the endothelium and increased in number between 71 
E10.5 and E12.5 alongside SVP expansion (Fig. 1a-c; Extended Data Fig. 1a). Csf1r-iCre-72 
targeting of vessel-bound cells was not an artefact caused by spontaneous recombination of the 73 
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RosaYfp reporter or unspecific immunostaining, because RosaYfp littermates lacking Csf1r-iCre also 74 
lacked YFP staining (Fig. 1a). Furthermore, immunostaining of Csf1r-iCre hindbrains carrying 75 
CAG-Cat-Egfp as an alternative recombination reporter or imaging of tdTomato (tdTom) 76 
fluorescence in Csf1r-iCre hindbrains with the RosatdTom reporter confirmed targeting of both 77 
microglia and vessel-bound elongated cells (Extended Data Fig. 1b,c). The independently 78 
generated Csf1r-Mer-iCre-Mer transgene, in which tamoxifen treatment is required for CRE 79 
activation 22, also targeted both vessel-bound cells and microglia in E12.5 hindbrains (Fig. 1d).  80 
Immunolabelling of E12.5 Csf1r-iCre;RosaYfp hindbrains for YFP and the macrophage marker 81 
F4/80 (ADGRE1) or the pericyte marker NG2 excluded that vessel-bound YFP+ cells were 82 
microglia/perivascular macrophages or pericytes (Extended Data Fig. 1d,e). Instead, 83 
immunolabelling for the EC-specific transcription factor ERG and surface marker PECAM1 (CD31) 84 
showed that vessel-bound, elongated Csf1r-iCre-targeted cells were ECs (Fig. 1e). Accordingly, 85 
their morphology was similar to ECs targeted with CRE encoded by the Cdh5-CreERT2 transgene, 86 
which is expressed in ECs but not microglia 23 and was activated by low dose tamoxifen treatment 87 
(Fig. 1e). Moreover, Csf1r-iCre-targeted ECs formed CDH5+ junctions with neighbouring non-88 
targeted ECs (Extended Data Fig. 1f).  89 
Immunolabelling of E11.5 Csf1r-iCre;RosaYfp hindbrains showed that microglia were CSF1R+ YFP+, 90 
as expected, but neither YFP- nor YFP+ ECs expressed the CSF1R protein (Extended Data Fig. 91 
2a). To determine whether the Csf1r promoter is active in ECs despite their lack of CSF1R protein 92 
expression, we used a Csf1r-Egfp transgene that faithfully reports Csf1r promoter activity as EGFP 93 
expression 24, 25. However, unlike microglia, ECs were not EGFP+ (Extended Data Fig. 2b). 94 
Further, the analysis of publicly available transcriptomic datasets 26 showed that Csf1r is neither 95 
expressed in E14.5 brain nor liver or lung ECs (Extended Data Fig. 2c). Finally, fluorescence-96 
activated cell sorting (FACS) of Csf1r-iCre-lineage traced (tdTom+) ECs and MCs with antibodies 97 
for PECAM1 versus the pan-hematopoietic marker CD45 (PTPRC) showed that tdTom+ PECAM1- 98 
CD45+ MCs expressed Csf1r, whereas tdTom+ PECAM1+ CD45- ECs expressed Cdh5, but not the 99 
the myeloid marker Spi1 (Pu.1) or Csf1r (Extended Data Fig. 2d-g). Putative Csf1r expression by 100 
a subset of brain ECs therefore does not explain Csf1r-iCre-mediated endothelial targeting. 101 
 102 
Csf1r-iCre-targeted ECs and EMPs are PU.1-independent and share spatiotemporal origins 103 
Lack of endothelial CSF1R expression suggests that Csf1r-iCre-targeted brain ECs arise from 104 
precursors that activate Csf1r prior to their incorporation into hindbrain vasculature. By examining 105 
Csf1r-iCre;RosaYfp hindbrains from Pu.1 (Spi1)-null mice, we excluded that Csf1r-iCre-targeted 106 
ECs were derived from differentiated MCs or the recently identified tissue-resident myeloid 107 
precursors of pericytes 4, 23. Thus, we found that PU.1 deficiency prevented the formation of YFP+ 108 
F4/80+ IB4+ microglia, as expected, but did not reduce the number of YFP+ IB4+ F4/80- ECs (Fig. 109 
1f-h). Microglia were also absent from the striatum of Csf1r-iCre;RosaYfp;Pu.1-/- brains on postnatal 110 
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day (P) 0, although YFP+ ECs were present (Extended Data Fig. 2h).  111 
As PU.1 is not required for EMP formation 27, we investigated whether the formation of Csf1r-iCre-112 
targeted ECs is mechanistically linked to the emergence of Csf1r+ EMPs. E8.5 Csf1r-Egfp yolk 113 
sacs contained clusters of round EGFP+ VEGFR2+ cells that protruded from VEGFR2+ endothelium 114 
into the vascular lumen (Fig. 2a), consistent with previously described EMP budding 14 and prior 115 
work showing that EMPs express Csf1r 10 and Vegfr2 12. Csf1r-iCre lineage tracing similarly 116 
identified round VEGFR2+ cells that protruded into the yolk sac vascular lumen (Fig. 2b), including 117 
round cells that expressed the EMP marker KIT 10 and persisted in PU.1-deficient yolk sacs at E8.5 118 
(Fig. 2c; Extended Data Fig. 3a,b). The endothelium of vessels in Csf1r-iCre;RosaYfp yolk sacs 119 
additionally contained larger and flatter YFP+ VEGFR2+ cells, which lacked active Csf1r expression 120 
(compare Fig. 2a with 2b). These cells also lacked KIT, but were PU.1-independent (Fig. 2c; 121 
Extended Data Fig. 3b), similar to Csf1r-iCre-targeted hindbrain ECs.  122 
Tamoxifen-induced, CRE-mediated reporter recombination is highest approximately 6 h after and 123 
ends 24 h after injecting a single tamoxifen dose into a pregnant dam 28, allowing us to activate 124 
Csf1r-Mer-iCre-Mer;RosatdTom in discrete temporal windows at E8.5, E9.5 or E10.5 before 125 
identifying lineage-traced cells in E12.5 yolk sacs by immunostaining (Extended Data Fig. 3c). 126 
Yolk sac macrophages were labelled after E8.5 induction (Extended Data Fig. 3d), consistent with 127 
their origin from early Csf1r+ EMPs 10. Induction at E9.5 or E10.5 also labelled yolk sac 128 
macrophages, likely because macrophages express Csf1r from E9.5 onwards 13, 15. Induction at 129 
E8.5 or E9.5 additionally yielded tdTom+ yolk sac ECs, whereas induction at E10.5 did not 130 
(Extended Data Fig. 3d). As EMPs are present in the yolk sac at E8.5 and E9.5, but home to the 131 
liver thereafter 16, their local availability makes them plausible precursors of Csf1r-iCre-labelled 132 
yolk sac ECs. In agreement, tamoxifen induction of a KitCreERT2 knockin allele 29 at E8.5, when KIT+ 133 
EMPs are in the yolk sac 14, labelled VEGFR2+ ERG+ yolk sac ECs alongside macrophages 134 
(Extended Data Fig. 3e,f).  135 
A recent study showed that late wave EMPs lack Csf1r expression when they form 10. To 136 
investigate whether these EMPs express Csf1r after their liver homing, we paired Csf1r-Mer-iCre-137 
Mer;RosatdTom with Csf1r-Egfp mice and induced pregnant dams with tamoxifen at E10.5 before 138 
analysing E11.5 liver cells via FACS to distinguish differentiated MCs and EMPs 10, 13, 14. We 139 
observed tdTom+ Csf1r-Egfp+ cells in the KIT- CD45+ differentiated MC population, as expected, 140 
but also in the KIT+ CD45lo progenitor population that includes EMPs (Fig. 3a,b; Extended Data 141 
Fig. 3g-I; KIT+ CD45- cells were neither MCs nor EMPs, because they lacked CD45, tdTom and 142 
EGFP). Blood cell analysis showed that cells from the Csf1r-Egfp+ tdTom+ KIT+ CD45lo population 143 
that includes EMPs was still circulating at E11.5 and therefore could access embryonic organ 144 
vasculature (Fig. 3a,b).  145 
To investigate whether Csf1r expression by late wave intraembryonic EMPs correlated with the 146 
emergence of Csf1r-iCre-targeted hindbrain ECs, we induced Csf1r-Mer-iCre-Mer;RosatdTom 147 
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embryos at E8.5, E9.5 or E10.5 and visualised tdTom expression in E12.5 hindbrains (Fig. 3c). 148 
Microglia were targeted at all three stages, consistent with their origin from early Csf1r-expressing 149 
EMPs and their active Csf1r expression; in contrast, hindbrain vasculature contained tdTom+ ECs 150 
following induction at E10.5, but not E8.5 or E9.5 (Fig. 3d). Accordingly, intraembryonic Csf1r-151 
iCre-targeted ECs emerge at a time when late wave EMPs have moved from the yolk sac into the 152 
embryo proper and have activated Csf1r expression 10. KitCreERT2 induction at E8.5, when both early 153 
and late KIT+ EMPs are present in the yolk sac, caused microglia targeting (Fig. 3e,f), suggesting 154 
that microglia can still be generated around E8.5 from KIT+ progenitor-derived yolk sac 155 
macrophages 11. This approach also yielded tdTom+ ECs in the E12.5 hindbrain and therefore 156 
corroborated that yolk sac-born EMPs can give rise to intraembryonic ECs. Lineage tracing from 157 
three independent Cre alleles therefore suggests that EMPs can differentiate into ECs.  158 
 159 
The Csf1r-iCre-targeted EMP lineage gives rise to ECs in vitro 160 
The myeloid and erythroid potential of EMPs has been demonstrated through in vitro differentiation 161 
assays 14, 30. To investigate their endothelial potential, we FACS-isolated KIT- CD45+ PECAM1- 162 
differentiated MCs and the KIT+ CD45lo PECAM1- population that contains EMPs from E12.5 163 
Csf1r-iCre;RosatdTom liver and blood, and then used these cell populations for in vitro differentiation 164 
that were combined with immunolabelling for myeloid and EC markers. Both populations were 165 
mostly tdTom+ (Fig. 4a,b). As expected 10, the EMP population was comprised of large round cells 166 
with a large nucleus and little cytoplasm, whereas the MC population contained granulocytes as 167 
well as monocytes in the liver and macrophages in the blood (Fig. 4a,b). We next cultured both 168 
cell populations in methocult, which promotes the formation of hematopoietic colonies, but 169 
additionally included a fibronectin substrate to facilitate EC differentiation. The differentiated 170 
tdTom+ MCs from both the liver and blood persisted as single round/amoeboid cells (Fig. 4c,d) that 171 
were ERGlo VEGFR2lo (Fig. 4e,f; secondary antibody only controls in Extended Data Fig. 4a,b). In 172 
contrast, the tdTom+ EMP populations from both the liver and blood formed myeloid and erythroid 173 
cell colonies in suspension (Fig. 4c,d). Moreover, both the EMP populations gave rise to single 174 
adherent cells, which resembled ECs due to their spindle-shaped/elongated morphology, lacked 175 
myeloid cell markers and were ERGhi VEGFR2hi, consistent with an EC identity (Fig. 4e,f; 176 
Extended Data Fig. 4b,c). In contrast, most neighbouring, adherent round/amoeboid cells 177 
expressed markers indicative of MC differentiation, including CD45, F4/80 or CSF1R (Fig. 4e,f; 178 
Extended Data Fig. 4c). Together, these experiments demonstrate that EMPs have endothelial 179 
potential alongside their known hematopoietic capacity. 180 
 181 
Csf1r-iCre-targeted ECs support the growth of embryonic brain vasculature 182 
Hoxa cluster genes regulate haematopoiesis 31 and are upregulated in postnatal compared to adult 183 
ECs 32, with HOXA9 also shown to promote EC differentiation from progenitor cells in adult 184 
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ischemic disease 33. Our analysis of published transcriptomic data 12, 34 revealed that several Hoxa 185 
transcripts are enriched in E10.25 compared to E9.0 EMPs or differentiated macrophages (Fig. 186 
5a). To investigate whether Hoxa-deficiency impaired the formation of EMP-derived ECs, we 187 
crossed Csf1r-iCre and RosatdTom into mice carrying a conditional null Hoxa cluster mutation 188 
(Hoxafl) 35 (Extended Data Fig. 5a). Gene copy analysis showed effective gene targeting in KIT+ 189 
cells from E12.5 Csf1r-iCre;Hoxafl/fl mutant compared to control livers, but the number of CD45+ 190 
cells, including differentiated MCs, was not reduced (Extended data Fig. 5b-f). These findings 191 
suggest that Hoxa genes are dispensable for MC specification from late wave EMPs. In contrast, 192 
significantly fewer tdTom+ ECs, also derived from late wave EMPs, had formed in Csf1r-193 
iCre;RosatdTom;Hoxafl/fl mutant compared to control hindbrains; moreover, SVP complexity was 194 
significantly reduced in the mutant compared to control hindbrains (Fig. 5b-d). Although we also 195 
observed 20% fewer microglia in mutant compared to control hindbrains (Extended data Fig. 5g-196 
i), this unlikely contributed to the vascular defect, because even 50% fewer microglia in Csf1op/+ 197 
mutants did not reduce SVP complexity (Extended data Fig. 5j-l). Together, these findings 198 
suggest that Hoxa cluster genes promote the formation of EMP-derived brain ECs, which in turn 199 
support normal brain vascular development.  200 
 201 
The EMP-derived EC population has a core endothelial transcriptional signature with 202 
enrichment for liver EC markers  203 
As Csf1r-iCre-targeted ECs appeared morphologically similar to neighbouring ECs (e.g. Fig. 1), 204 
with similarly slow proliferation and overall cell cycle kinetics (Extended Data Fig. 6), we next 205 
compared the gene expression signature of both EC types by RNAseq. Thus, we used E12.5 206 
Csf1r-iCre;RosatdTom embryos for FACS to separate tdTom+ and tdTom- ECs, defined as PECAM1+ 207 
cells lacking KIT, CD45 and CD11b (ITGAM) (Fig. 6a). Both EC populations differed by their 208 
expression of the Rosa transcript, as expected (Extended Data Fig. 7a), but otherwise had largely 209 
similar transcriptomes with few differentially expressed genes (Fig. 6b,c). Consistent with an 210 
endothelial identity, tdTom+ ECs lacked markers for differentiated MCs and other non-EC lineages, 211 
but expressed transcripts for core EC markers at similar levels as tdTom- ECs (Fig. 6d,e).  212 
Amongst the differentially expressed genes, markers typical of EC specialisation were under-213 
represented in tdTom+ ECs, such as ephrins and their EPH receptors, which regulate 214 
arteriovenous differentiation, or Slc2a1, a marker of brain EC maturation (Fig. 6c,e,f). Reverse 215 
transcriptase quantitative PCR (RT-qPCR) comparisons confirmed that the brain EC maturation 216 
marker Slc2a1 was expressed at lower levels in tdTom+ than tdTom- ECs at E12.5, consistent with 217 
delayed endothelial differentiation (Extended data Fig. 7b). This observation agrees with the idea 218 
that Csf1r-iCre lineage-traced ECs in the brain are derived from circulating progenitors that are 219 
recruited into a vascular endothelium that is pre-formed by ECs of classical origin. Whereas Slc2a1 220 
and other markers of brain ECs were under-represented in the embryo-wide tdTom+ EC 221 
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population, liver EC markers were over-represented (e.g. Oit3, Mrc1), including early markers of 222 
liver sinusoidal differentiation (Stab2 and Lyve1) 36 (Fig. 6c,f). These observations were confirmed 223 
by RT-qPCR (Extended data Fig. 7b,c). RT-qPCR confirmed that liver transcripts were expressed 224 
at similar levels in tdTom+ and tdTom- liver ECs (Extended Data Fig. 7d), thereby corroborating 225 
that EMP- and non-EMP-derived ECs are overall similar. Moreover, this finding suggested that the 226 
over-representation of liver EC transcripts in the total embryonic EC population reflected a 227 
preferential contribution of EMP-derived vascular progenitors to liver vasculature rather than 228 
altered liver EC differentiation. Immunostaining and flow cytometry of Csf1r-iCre;RosatdTom E12.5 229 
and E18.5 embryos confirmed that tdTom+ ECs were more prevalent in liver endothelium than 230 
tdTom- ECs (Fig. 6g,i; Extended Data Figs. 8 and 9a,b). Agreeing with the RT-qPCR analysis, 231 
MRC1 as well as LYVE1 were observed in both tdTom- and tdTom+ ECs within E12.5 liver 232 
vasculature (Fig. 6g; Extended Data Fig. 8a). Liver ECs of two distinct origins therefore undergo 233 
similar organ-specific EC differentiation. 234 
 235 
Csf1r-iCre-targeted ECs populate multiple embryonic organs and persist into adulthood  236 
Immunostaining and FACS analyses at E18.5 confirmed that Csf1r-iCre-targeted ECs contribute to 237 
brain and liver, but also heart and lung vasculature (Fig. 6i; Extended Data Fig. 8 and 9a,b). 238 
EMPs therefore contribute to organ vasculature at multiple sites (working model in Extended Data 239 
Fig. 9c). Corresponding immunostaining and FACS analyses of adult organs showed that tdTom+ 240 
ECs persisted in the brain, heart, lung and liver (Fig. 6h,j; Extended Data Fig. 10). Moreover, 241 
tdTom+ ECs continued to dominate the LYVE1+ MRC1+ liver sinusoidal endothelium of adult mice 242 
(Fig. 6h,j; Extended Data Fig. 10b). Accordingly, organs differ with respect to their content of 243 
EMP-derived ECs, with a remarkably high contribution to liver sinusoidal endothelium in both 244 
embryos and adults.   245 
 246 
Discussion  247 
The heterogeneous origin of blood vascular mural cells from distinct populations of mesodermal 248 
progenitors, hematopoietic and neural crest cells is established 37. Here, we have combined 249 
constitutive and temporally inducible lineage tracing with FACS, immunostaining, transcriptomic 250 
analyses and cell culture assays to show that embryonic vascular endothelium has two major 251 
origins: a classical origin via angioblast differentiation into ECs and the unexpected differentiation 252 
of ECs from the EMP lineage. Multiple prior investigations have utilised the Csf1r-iCre transgene 253 
together with recombination reporters to follow the embryonic myeloid lineage 10, 13, 15. These 254 
studies predominantly employed flow cytometry with hematopoietic markers, which precluded the 255 
observation of Csf1r-iCre-targeted ECs. In contrast, we included EC markers to isolate Csf1r-iCre-256 
targeted ECs alongside MCs from embryonic and adult organs. Immunostaining of tissues was 257 
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previously also used to identify Csf1r-iCre-targeted cells in the retina 20, liver and colon 21, but 258 
without description of EC targeting, possibly because of the close spatial proximity of ECs and 259 
perivascular macrophages 4, 6. By performing high resolution imaging after immunostaining for EC 260 
and macrophage makers, we have overcome this limitation to demonstrate targeting of both cell 261 
types alongside each other in situ. The contribution of EMP-derived ECs to yolk sac, brain, heart 262 
and lung vasculature is proportionally smaller than that of ECs of classical origin, whereas EMP-263 
derived ECs predominate the liver, particularly the sinusoidal endothelium. Liver endothelium was 264 
previously reported to be heterogeneous in origin, with an endoderm lineage contribution of 265 
approximately 15% and the remainder of the liver EC population attributed to a venous origin, i.e. 266 
angiogenic ingrowth from nearby veins 38. Our results suggest that liver endothelium additionally 267 
contains approximately 60% EMP-derived ECs, accordingly decreasing prior estimates for liver 268 
ECs of venous origin. Preferential EMP homing to the liver after their entry into the embryonic 269 
circulation 16 and the dependence of liver growth on rapid vascular expansion 39 may explain the 270 
relatively large contribution of EMP-derived ECs to this organ. Ultimately, the discovery that EMPs 271 
provide a source of ECs for organ vasculature may open up new therapeutic avenues for vessel-272 
dependent organ repair and regeneration. For example, EMPs or EMP-like EC progenitors, 273 
derived from human stem cells via genetic manipulation of factors such as or including Hoxa 274 
genes, may be delivered systemically to support vascular growth in ischemic diseases or provide 275 
angiocrine signals that stimulate tissue stem cells. 276 
 277 
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Figure legends 388 
 389 
Fig. 1: Csf1r-iCre lineage tracing identifies ECs in developing brain vasculature. 390 
(a) Confocal z-stacks of hindbrains of the indicated genotypes and gestational stages, wholemount 391 
labelled for YFP and IB4, identified Csf1r-iCre targeting of vessel-bound cells during hindbrain 392 
vascularisation. (b) Number of YFP+ IB4+ single cells (microglia) and YFP+ IB4+ vessel-bound cells 393 
(putative ECs) per 0.72 mm2; mean ± SD, n=3 hindbrains each. (c) Correlation between vessel 394 
area and number of YFP+ putative ECs; r2, coefficient of determination; P < 0.01; each data point 395 
represents the value of one hindbrain.  396 
(d) Confocal z-stack of an E12.5 Csf1r-Mer-iCre-Mer;RosatdTom hindbrain after tamoxifen delivery 397 
on E10.5, IB4 wholemount labelled and shown including tdTom fluorescence.  398 
(e) Confocal z-stacks of Csf1r-iCre;RosatdTom and Cdh5-CreERT2;RosatdTom  E12.5 hindbrains, 399 
wholemount labelled for the endothelial markers ERG and PECAM1 and shown including tdTom 400 
fluorescence to demonstrate that Csf1r-iCre targets ECs; Cdh5-CreERT2 was induced with a low 401 
tamoxifen dose at E11.5.  402 
(f-h) Confocal z-stacks of Csf1r-iCre;RosaYfp E11.5 hindbrains on a Pu.1+/+ versus Pu.1-/- 403 
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background, wholemount labelled for YFP and F4/80 together with IB4, show that Csf1r-iCre-404 
targeted ECs are PU.1-independent. The boxed area in (f) was 3D surface rendered and is shown 405 
in (g) en face and as a lateral view starting at the plane indicated by the yellow line; the stippled 406 
line outlines the vascular lumen (lu). (h) Quantification of YFP+ microglia (Pu.1+/+ n=4; Pu.1-/- n=3) 407 
and ECs (Pu.1+/+ n=6; Pu.1-/- n=7); mean ± SD; each data point represents the value for one 408 
hindbrain; n.s., non-significant, * P > 0.05 (unpaired t-test).  409 
Symbols: Microglia and ECs are indicated with arrowheads and arrows, respectively. Solid and 410 
clear symbols indicate the presence or absence of marker expression, respectively.  411 
Scale bars: 20 µm (a,d,f), 50 µm (e). 412 
 413 
Fig. 2: Csf1r-iCre-targeted ECs emerge concomitantly with EMPs in the yolk sac. 414 
Confocal z-stacks of E8.5 yolk sacs from Csf1r-Egfp mice (a) or Csf1r-iCre;RosaYfp mice on a 415 
Pu.1+/+ versus Pu.1-/- background (b), wholemount labelled for VEGFR2 and EGFP (a) or YFP (b). 416 
Lateral views of 3D-rendered yolk sac vasculature starting at the positions indicated by cyan and 417 
orange lines show lineage-traced YFP+ VEGFR2+ flat cells in the vascular wall and VEGFR2+ 418 
round cells expressing EGFP or YFP, respectively, protruding from the vascular wall into the lumen 419 
(lu). Symbols: Wavy arrows indicate EGFP+ or YFP+ VEGFR2+ EMPs/MPs, straight arrows YFP+ 420 
VEGFR2+ ECs. Scale bars: 20 µm. 421 
 422 
Fig. 3: Csf1r-iCre-targeted hindbrain ECs emerge from intraembryonic EMPs.  423 
(a,b) A pregnant Csf1r-Egfp;Csf1r-Mer-iCre-Mer;RosatdTom dam was injected with a single 424 
tamoxifen dose on E10.5 (a) before E11.5 liver and blood cells were analysed by flow cytometry 425 
(b) for CD45 and KIT, followed by gating the CD45hi KIT- differentiated MC (blue) and CD45lo KIT+  426 
EMP/myeloid progenitor (MP) populations (pink) for EGFP and tdTom (n=4 embryos).  427 
(c-f) Pregnant Csf1r-Mer-iCre-Mer;RosatdTom (c,d) and KitCreERT2;RosatdTom (e,f) dams were injected 428 
with a single tamoxifen dose on the indicated days and confocal z-stacks obtained of E12.5 429 
hindbrains after wholemount staining for the indicated markers, shown including tdTom 430 
fluorescence. Symbols: Arrows indicate tdTom+ ECs, arrowheads macrophages and microglia and 431 
wavy arrows a cluster of tdTom+ ERG- IB4- neural progenitors, which express Kit at E8.5. Scale 432 
bars: 20 µm. 433 
 434 
Fig. 4: EMPs in the liver and blood give rise to ECs in vitro.  435 
(a,b) FACS gating strategy for separation of the indicated cell populations, including EMP lineage 436 
cells, from E12.5 Csf1r-iCre;RosatdTom liver (a) and blood (b) using antibodies for PECAM1, CD45 437 
and KIT (top), including proportion of cells with tdTom recombination in the MC and EMP/MP 438 
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populations and Giemsa-Wright staining of representative cells (bottom); Mo, monocyte; GC, 439 
granulocyte; MΦ, macrophage.  440 
(c,d) Brightfield images of hematopoietic colonies formed after three days in methocult (met.); note 441 
white and reddish colour of myeloid and erythroid colonies, respectively. (e,f) Fibronectin (FN)-442 
adherent cells after three days in methocult were immunolabelled for the EC markers ERG and 443 
VEGFR2 and counterstained with the nuclear label DAPI. Symbols: Arrows indicate tdTom+ ECs, 444 
arrowheads tdTom+ MCs. Solid and clear symbols indicate high versus low level expression, 445 
respectively, of the indicated markers. Scale bars: 20 µm. 446 
 447 
Fig. 5: Csf1r-iCre-targeted ECs form in a Hoxa-dependent mechanism and promote 448 
vascularisation in the embryonic hindbrain. 449 
(a) Transcriptomic analysis of the indicated cell populations, based on published RNAseq and EC 450 
microarray data 12, 34 (n ≥ 2), shows that Hoxa genes are enriched in intraembryonic EMPs; white 451 
represents low and black high relative expression levels of the indicated genes. 452 
(b) Confocal z-stacks of E12.5 littermate hindbrains of the indicated genotypes, wholemount 453 
labelled for F4/80, RFP to visualise tdTom and with IB4. Symbols: Arrows and arrowheads indicate 454 
tdTom+ ECs and microglia, respectively.  Scale bars: 50 µm. 455 
(c) Percentage of tdTom+ relative to IB4+ EC volume in Hoxa+/+ (n=3) versus Hoxafl/fl mutant (n=7) 456 
hindbrains on a Csf1r-iCre;RosatdTom background. (d) Number of vascular branchpoints in control 457 
(pooled Csf1r-iCre+;Hoxa+/+ and Csf1r-iCre- of any Hoxa genotype; n=13) versus Hoxafl/fl;Csf1r-iCre 458 
mutant (n=9) hindbrains. Mean ± SD fold change; each data point represents the value for one 459 
hindbrain; * P < 0.05 (unpaired t-test).   460 
 461 
Fig. 6: Csf1r-iCre-targeted ECs have a core endothelial transcription signature with an 462 
increase in liver EC transcripts, and they persist in adult organ vasculature.  463 
(a) FACS of PECAM1+ CD45- CD11b- KIT- cells from E12.5 Csf1r-iCre;RosatdTom embryos, 464 
including gating to separate tdTom- and tdTom+ ECs for RNAseq. (b) Graphic representation of 465 
genes whose expression is significantly different (green dots) or similar (black dots) between both 466 
EC populations. (c) Volcano plot of 247 transcripts with on average > 100 counts that are 467 
significantly different between both populations; grey and red data points represent transcripts in 468 
tdTom- ECs with ≥2-fold over- or under-representation, respectively, with selected genes named. 469 
(d-f) Relative expression levels in both EC populations of (d) non-EC markers typical of myeloid 470 
(Cx3cr1-Ptprc), astrocytic (Gfap), smooth muscle (Acta2), neuronal (Rbfox3, Nefl), skeletal muscle 471 
(Myog) or epithelial (Cdh1) differentiation, (e) core EC or EC maturation markers and (f) 472 
representative brain or liver EC specialisation markers, shown alongside their relative expression 473 
in brain versus liver/lung ECs based on microarrays 31. RNAseq analysis: mean of normalised 474 
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counts ± SD, n=3 samples each (DESeq2; Benjamini-Hochberg’s multiple comparisons test for p-475 
value adjustment, adjP). Microarray analysis: mean ± SD, n=5 samples each (2-way ANOVA, 476 
Bonferroni’s multiple comparisons test). * P < 0.05, ** P < 0.01, *** P < 0.001, ns, non-significant. 477 
(g,h) Csf1r-iCre;RosatdTom E12.5 (g) and adult (h) liver cryosections were labelled for the indicated 478 
markers and RFP to visualise tdTom, including DAPI counterstaining in (h). Symbols: Arrows and 479 
arrowheads indicate tdTom+ ECs and macrophages, respectively. Clear arrowheads indicate 480 
VEGFR2- macrophages.  Scale bar: 50 µm. 481 
(i,j) The relative contribution of tdTom+ ECs to organ vasculature at E12.5 (i) and in 12-week old 482 
adult mice (j) was determined by flow cytometry of Csf1r-iCre;RosatdTom brain, heart, lung and liver. 483 
Mean ± SD; n ≥ 4 (E12.5) and n ≥ 6 (adult), with each data point representing an individual organ 484 
(1-way ANOVA, Tukey’s multiple comparisons test, ** P < 0.01, *** P < 0.001).  485 
 486 
  487 
   
- 15 - 
(online only) Methods plus associated references 488 
 489 
Mouse strains. All animal procedures were performed in accordance with the institutional Animal 490 
Welfare Ethical Review Body (AWERB) and UK Home Office guidelines. To obtain mouse 491 
embryos of defined gestational age, mice were paired in the evening and the presence of a vaginal 492 
plug the following morning was defined as E0.5. In some studies, we analysed adult mice, defined 493 
as more than 8 weeks of age.  Mice carrying the Csf1r-iCre transgene 21 were mated to RosaYfp 40, 494 
RosatdTom 41 or CAG-cat-Egfp 42 mice. PU.1 heterozygous null mice 43 were mated to RosaYfp mice 495 
and then Csf1r-iCre mice to obtain Csf1r-iCre;RosaYfp;Pu.1-/- embryos. Hoxafl/fl mice 35 were mated 496 
to RosatdTom mice and then Csf1r-iCre to obtain Csf1r-iCre;RosatdTom;Hoxafl/fl embryos. Csf1r-Mer-497 
iCre-Mer 22, Cdh5-Cre-ERT2 44 and KitCreERT2 mice 29 were mated to RosatdTom mice. We also used 498 
Csf1r-Egfp-Ngfr/Fkbp1a/Tnfrsf6 (short: Csf1r-Egfp) mice as a reporter of Csf1r expression 25 and a 499 
loss of function mutation in Csf1 (Csf1Op) 45. All mouse strains were maintained on a mixed 500 
background (C57Bl6/J;129/Sv), with the exception of Csf1r-Mer-iCre-Mer, which was maintained 501 
on a mixed FVB:C57/bl6 background. For tamoxifen induction of CRE activity, tamoxifen (Sigma) 502 
was dissolved to 2 mg/ml in peanut oil and administered via intraperitoneal injection into pregnant 503 
dams. For Cdh5-Cre-ERT2 and Csf1r-Mer-iCre-Mer, we injected 20 μg and 1 mg tamoxifen alone, 504 
respectively; for KitCre-ERT2, we injected 3 mg tamoxifen together with 1.75 mg progesterone 505 
(Sigma).  506 
Immunolabelling. Samples were fixed in 4% formaldehyde in PBS and processed as either 507 
wholemount or 20 µm cryosections. Immunolabelling was performed as described previously 46 508 
using the following antibodies and dilutions: goat anti-CDH5 (1:200; AF1002, lot FQI0116101, R&D 509 
Systems), rabbit anti-CSF1R (1:500; sc-692, lot K1212, Santa Cruz), rat anti-EMCN (1:50; sc-510 
65495, lot C2917, Santa Cruz), rabbit anti-ERG (1:200; ab92513, lot GR32027 69-1, Abcam), rat 511 
anti-F4/80 (1:500; MCA497R, lot 1605, Serotec), chicken anti-GFP (1:1000; GFP-1020, lot 512 
0511FP12, Aves) and rabbit anti-GFP (1:500; 598, lot 079, MBL) for YFP or EGFP labelling, rabbit 513 
anti-IBA1 (1:500; 019-19741, Wako Chemicals), rat anti-KIT (1:500; 553353, lot 30259, BD 514 
Pharmingen), rabbit anti-NG2 (1:200; AB5320, lot 2726769, Millipore), rat anti-PECAM1 (1:200; 515 
553370, lot 5205656, BD Pharmingen), rabbit anti-pHH3 (1:400; 06-570, lot 2825969, Millipore), 516 
rabbit anti-RFP (1:1000; PM005, lot 045, MBL), goat anti-VEGFR2 (1:200; AF644, lot 517 
COA0417021, R&D Systems). Secondary antibodies used included Alexa Fluor-conjugated goat 518 
anti-chick, -rabbit or -rat IgG (Life Technologies), or, for primary antibodies raised in goat, donkey 519 
fluorophore-conjugated FAB fragments of anti-chick, -goat, -rabbit or -rat IgG (Jackson 520 
ImmunoResearch). Biotinylated IB4 (L2140, lot 085M4032V, Sigma) followed by Alexa-conjugated 521 
streptavidin (ThermoFisher) was used to detect brain endothelial cells and microglia 4, 19. Nuclei 522 
were labelled with DAPI. Images were acquired with a LSM710 laser scanning confocal 523 
microscope (Zeiss) and processed using LSM image browser (Zeiss) and Photoshop CS4 (Adobe) 524 
software. Three-dimensional rendering including surface rendering and the generation of virtual 525 
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slices for lateral views of high-resolution confocal z-stacks was carried out with Imaris (Bitplane). 526 
Fluorescence-activated cells sorting (FACS) and cell culture. Tissues were mechanically and 527 
enzymatically homogenised in RPMI1640 with 2.5% foetal bovine serum (ThermoFisher), 100 528 
µg/ml collagenase/dispase (Roche), 50 µg/ml DNAse (Qiagen) and 100 µg/ml heparin (Sigma), 529 
incubated for 5 mins with 0.5 mg/ml rat Fc block (Becton Dickinson) and labelled with a 530 
combination of PE/Cy7-conjugated rat anti-PECAM1 (clone 390, cat 102418, lot B212262), FITC-531 
conjugated rat anti-CD45 (clone 30-F11, cat 103108, lot B246762) or CD41 (clone MWReg30, cat 532 
133903, lot B201955), APC-conjugated rat anti-KIT (clone 2B8, cat 105812, lot B217855) and 533 
PerCp/Cy5.5-conjugated rat anti-CD11b (clone M1/70, cat 101227) (all Biolegend). Appropriate 534 
fluorescence gate parameters were established with unstained tissue, Csf1r-iCre- or Csf1r-Egfp-535 
negative tissues and fluorescence-minus-one (FMO) staining. For cell cycle analysis, cell 536 
populations were incubated with 10 µg/ml Hoechst 33342 (Sigma) for 30 mins at 37˚C 47 before 537 
labelling with PE/Cy7-conjugated rat anti-PECAM1 and performing FACS analysis. In all 538 
experiments, doublets were eliminated using pulse geometry gates (FSC-H versus FSC-A and 539 
SSC-H versus SSC-A), whereas dead cells were removed using SYTOX Blue (Life Technologies) 540 
or LIVE/DEAD Fixable Violet (Life Technologies). Single cell suspensions were analysed using the 541 
BD LSRFortessa X-20 cell analyser or sorted using the BD Influx cell sorter (BD Biosciences); 542 
FlowJo software (FlowJo LLC) was used for subsequent analyses. In some experiments, a fraction 543 
of each population was cytospun onto a glass slide for Wright-Giemsa staining (Sigma) followed by 544 
imaging using an LSM510 microscope equipped with an AxioCam MRc camera (Zeiss). For cell 545 
culture experiments, cell populations were sorted into DMEM with 100 U/ml penicillin, 100 U/ml 546 
streptomycin and 20% foetal bovine serum (all ThermoFisher) before seeding the cells into a 96-547 
well plate coated with 10 µg/ml fibronectin (ThermoFisher). Cells were cultured in methocult 548 
(Stemcell Technologies); haematopoietic colonies were imaged using a TS100 microscope 549 
equipped with a DS-5M colour camera (Nikon). Adherent cells were fixed with 4% formaldehyde in 550 
PBS and then labelled for VEGFR2, ERG, CD45, F4/80 and CSF1R (see above) before imaging 551 
using a Ti-E microscope (Nikon).  552 
RNAseq. PECAM1+ CD45- CD11b- KIT- ECs were isolated from E12.5 Csf1r-Cre;RosatdTom 553 
embryos and divided into tdTom+ and tdTom- populations with the Influx cell sorter before RNA 554 
was extracted with the RNeasy Micro Kit (QIAGEN). cDNA was generated and amplified using the 555 
SMART-seq V4 ultra low input RNA kit (Clontech). 100 pg of amplified cDNA per sample was used 556 
to prepare a library with the Nextera XT kit (Illumina) and run on the NextSeq 500 sequencer 557 
(lllumina). Raw sequence data were pre-processed to trim poor quality base calls and adapter 558 
contamination using Trimmomatic v.0.36.4 48 and aligned to the mouse mm10 genome with STAR 559 
v.2.5.2b 49. Mapped reads were deduplicated to reduce PCR bias using Picard v2.7.1.1 software 560 
(http://broadinstitute.github.io/picard/), and the reads-per-transcript were then calculated using 561 
FeatureCount v1.4.6.p5 software 50. Differential expression was performed using the BioConductor 562 
package DESeq2 via the SARTools wrapper v1.3.2.0 51. 563 
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Reverse transcription polymerase chain reaction (PCR). We isolated cells with the Influx cell 564 
sorter (see above). We extracted RNA with the RNeasy Micro Kit and synthesised cDNA with 565 
Superscript IV (ThermoFisher). Quantitative (q) RT-PCR was performed with SYBR Green on an 566 
HT7900 system (Applied Biosystems) using the following oligonucleotide pairs: Actb 5’-567 
CACCACACCTTCTACAATGAG-3’ and 5’-GTCTCAAACATGATCTGGGTC-3’; Cdh5  568 
5’-GATGCAGATGACCCCACTGT-3’ and 5’-AGGGCATCTTGTGTTCCAC-3’; Csf1r 5’-569 
TGCGTCTACACAGTTCAGAG-3’ and 5’-ATGCTGTATATGTTCTTCGGT-3’; Spi1 5’-570 
GCCATAGCGATCACTACTG-3’ and 5’-CAAGGTTTGATAAGGGAAGC-3’; Hoxa11 5’-571 
TCTTTGCCTCTCTCCTTCCTT-3’ and 5’-TTGCAGACGCTTCTCTTTGTT-3’; Evx1 5’-572 
GTGTGCTCTGGGCTCCTGT-3’ and 5’-GCCAGGGTGCCTTGAGAG-3; Slc2a1 5’-573 
CCCCAGAAGGTTATTGAGGAGT and 5’-ACAAAGAGGCCGACAGAGAA; Mrc1 5’-574 
ACTGGGCAATGCAAATGGAG and 5’- CCCTCAAAGTGCAATGGACA; Oit3 5’-575 
CGTCTGCTTCCATGTCTACTG and 5’-GTGCTCACATTCATTTTCGTCA. For each 576 
oligonucleotide pair, a no-template control reaction was included.  577 
 578 
Microarray analysis. Published microarray data 26 were used to compare gene expression levels 579 
in E14.5 CD45- PECAM1+ brain versus pooled lung and liver ECs using GEO2R software (NCBI). 580 
Statistical Analysis. Tissues for analysis were allocated to experimental groups according to 581 
genotype and gestational age. The number of YFP+ ECs and YFP+ microglia in Csf1r-iCre;RosaYfp 582 
hindbrains (Fig. 1a,b and 1f-h) was determined in three randomly chosen 0.72 mm2 regions of 583 
each wholemount labelled and flatmounted hindbrain. For hindbrains in Hoxa-targeting 584 
experiments, the number of F4/80+ microglia (Extended Data Fig. 5) and tdTom+ and IB4+ volume 585 
(Fig. 5b,c) were determined from confocal z-stacks of four randomly chosen 0.18 mm2 regions on 586 
the lateral side of each hindbrain (Extended Data Fig. 5g). The z-stacks were surface rendered 587 
with Imaris (Bitplane) to obtain the F4/80+, tdTom+ and IB4+ volumes, and the F4/80+ volume was 588 
then subtracted from both the IB4+ and tdTom+ total volume to obtain the IB4+ EC and tdTom+ EC 589 
volume before calculating the ratio of tdTom+ to IB4+ EC volume. To determine the number of 590 
vascular intersections in Hoxa-targeting experiments (Fig. 5b,d), the same confocal z-stacks were 591 
analysed with Imaris filament tracer after F4/80+ microglia were masked. For Fig. 1 and Fig. 5, all 592 
counts obtained from one hindbrain were averaged to yield the value for that hindbrain; to ensure 593 
unbiased interpretation of results, the genotypes were disclosed only after data collection was 594 
complete. For all experiments, we calculated the mean value for at least 3 independent samples, 595 
where error bars represent the standard deviation of the mean (for details, see figure legends). 596 
Comparison of medians against means justified the use of a parametric test; to determine whether 597 
two datasets were significantly different, we therefore calculated p values with a two-tailed 598 
unpaired Student’s t test; P < 0.05 was considered significant. When more than two data sets were 599 
compared, we used the statistical tests indicated in the associated figure legends. Statistical 600 
analyses were performed with Excel 12.2.6 (Microsoft Office) or Prism 5 (GraphPad Software).  601 
   
- 18 - 
References specific to the online methods 602 
40. Srinivas, S. et al. Cre reporter strains produced by targeted insertion of EYFP and ECFP into 603 
the ROSA26 locus. BMC Dev Biol 1, 4 (2001). 604 
41. Madisen, L. et al. A robust and high-throughput Cre reporting and characterization system for 605 
the whole mouse brain. Nature neuroscience 13, 133-140 (2010). 606 
42. Kawamoto, S. et al. A novel reporter mouse strain that expresses enhanced green fluorescent 607 
protein upon Cre-mediated recombination. FEBS letters 470, 263-268 (2000). 608 
43. McKercher, S.R. et al. Targeted disruption of the PU.1 gene results in multiple hematopoietic 609 
abnormalities. The EMBO journal 15, 5647-5658 (1996). 610 
44. Zarkada, G., Heinolainen, K., Makinen, T., Kubota, Y. & Alitalo, K. VEGFR3 does not sustain 611 
retinal angiogenesis without VEGFR2. Proceedings of the National Academy of Sciences of 612 
the United States of America 112, 761-766 (2015). 613 
45. Yoshida, H. et al. The murine mutation osteopetrosis is in the coding region of the 614 
macrophage colony stimulating factor gene. Nature 345, 442-444 (1990). 615 
46. Vieira, J.M., Schwarz, Q. & Ruhrberg, C. Selective requirements for NRP1 ligands during 616 
neurovascular patterning. Development 134, 1833-1843 (2007). 617 
47. Goodell, M.A., Brose, K., Paradis, G., Conner, A.S. & Mulligan, R.C. Isolation and functional 618 
properties of murine hematopoietic stem cells that are replicating in vivo. The Journal of 619 
experimental medicine 183, 1797-1806 (1996). 620 
48. Bolger, A.M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence 621 
data. Bioinformatics 30, 2114-2120 (2014). 622 
49. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21 (2013). 623 
50. Liao, Y., Smyth, G.K. & Shi, W. featureCounts: an efficient general purpose program for 624 
assigning sequence reads to genomic features. Bioinformatics 30, 923-930 (2014). 625 
51. Varet, H., Brillet-Gueguen, L., Coppee, J.Y. & Dillies, M.A. SARTools: A DESeq2- and EdgeR-626 
Based R Pipeline for Comprehensive Differential Analysis of RNA-Seq Data. PloS one 11, 627 
e0157022 (2016). 628 
  629 
   
- 19 - 
Extended data figure legends: 630 
 631 
Extended data figure 1: Endothelial Csf1r-iCre targeting is observed with different 632 
recombination reporters and targeted ECs are distinguishable from macrophages and 633 
pericytes.  634 
(a-c) Confocal z-stacks of Csf1r-iCre;RosaYfp (a) Csf1r-iCre;CAG-Cat-Egfp (b) and Csf1r-635 
iCre;RosatdTom (c) hindbrains at the indicated stages were wholemount labelled with IB4 and YFP 636 
(a) or EGFP staining (b) or are shown together with tdTom fluorescence (c). In (a), the white 637 
squares indicate areas shown in higher magnification in Fig. 1a. The indicated single channels are 638 
also shown individually.  639 
(d,e) Confocal z-stacks of E12.5 Csf1r-iCre;RosaYfp hindbrains, wholemount labelled for YFP and 640 
the microglia marker F4/80 (d) or the pericyte marker NG2 (e) together with IB4 show that Csf1r-641 
iCre-targeted vessel-bound cells are neither microglia nor pericytes. In (d), the boxed area is 642 
shown in higher magnification and as single channels adjacent to the panel. In (e), a single optical 643 
y/z cross section at the position indicated with the yellow line is displayed at higher magnification 644 
with single channels.  645 
(f) Confocal z-stacks of a Csf1r-iCre;RosatdTom E12.5 hindbrains, wholemount labelled for ERG and 646 
CDH5 and shown including tdTom fluorescence to demonstrate that Csf1r-iCre targets bona fide 647 
ECs that form junctions with neighbouring ECs.  648 
Symbols: Microglia and ECs are indicated with arrowheads and arrows, respectively, pericytes with 649 
double arrowheads, junctional CDH5 staining with a curved arrow. Solid and clear symbols 650 
indicate the presence or absence of marker expression, respectively. Scale bars: 100 µm (a), 20 651 
µm (b-e), 50 µm (f). 652 
 653 
Extended data figure 2: Endothelial Csf1r-iCre-targeting is not caused by endothelial Csf1r 654 
expression and occurs independently of myeloid differentiation. 655 
(a,b) Confocal z-stacks of E11.5 Csf1r-iCre;RosaYfp (a) or Csf1r-Egfp (b) hindbrains, wholemount 656 
labelled for CSF1R and YFP or EGFP together with IB4, show lack of CSF1R protein and promoter 657 
activity in embryonic ECs. 658 
(c) Graphic representation of relative Cdh5 and Csf1r expression levels in E14.5 brain or pooled 659 
lung/liver EC microarrays 31; n = 5 each; *** P > 0.001 (unpaired t-test).  660 
(d-f) FACS separation of tdTom+ cells from Csf1r-iCre;RosatdTom embryos, including (d) 661 
representative gating strategy to exclude dead cells and doublets in this and subsequent 662 
experiments and (e) sorting into PECAM1+ CD45- ECs versus CD45+ PECAM1- MCs for RT-qPCR 663 
analysis. (f) Representative gene amplification graphs for Csf1r versus Actb from tdTom+ MCs and 664 
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ECs; ∆Rn, normalised reporter value for SYBR Green minus baseline instrument signals. (g) 665 
Graphic representation of the fold change in amplification of the indicated genes relative to Actb for 666 
both cell populations. Each data point represents the value of one embryo; n=3 each; * P > 0.05, 667 
*** P > 0.001 (unpaired t-test).  668 
(h) Confocal z-stacks of Csf1r-iCre;RosaYfp P0 striatum on a Pu.1+/+ versus Pu.1-/- background, 669 
wholemount labelled for YFP and F4/80 together with IB4, show that Csf1r-iCre-targeted ECs are 670 
PU.1-independent.  671 
Symbols: Arrowheads indicate microglia, arrows YFP+ ECs, clear arrows YFP+ ECs that are 672 
CSF1R- and F4/80-.   673 
Scale bars: 20 µm. 674 
 675 
Extended data figure 3: Lineage tracing of yolk sac and liver EMPs.  676 
(a,b) Confocal z-stacks of wholemount labelled E8.5 wild type (a) and Pu.1-/- (b) yolk sacs on a 677 
Csf1r-iCre;RosaYfp background, labelled for YFP and KIT, show Csf1r-iCre-targeted KIT+ round 678 
cells corresponding to EMPs/MPs and Csf1r-iCre-targeted KIT- flat cells corresponding to ECs.   679 
(c-f) Pregnant Csf1r-Mer-iCre-Mer;RosatdTom (c,d) and KitCreERT2;RosatdTom (e,f) dams were injected 680 
with a single tamoxifen dose on the indicated days; confocal z-stacks of E12.5 yolk sacs, 681 
immunolabelled for the indicated markers, show Csf1r-iCre-targeted ECs and macrophages.  682 
Symbols: Wavy arrows indicate EMPs, straight arrows Csf1r-iCre-lineage traced ECs, arrowheads 683 
macrophages. Solid and clear symbols indicate the presence or absence, respectively, of the 684 
indicated markers. Scale bars: 20 µm.  685 
(g-i) Pregnant dams were injected with a single tamoxifen dose on E10.5 (g) before analysis of 686 
E11.5 liver cells from Csf1r-Egfp;Csf1r-Mer-iCre-Mer;RosatdTom (h; n=4 embryos) or Csf1r-Mer-687 
iCre-Mer;RosatdTom embryos lacking Csf1r-Egfp (i; n=4 embryos) by flow cytometry for CD45 and 688 
KIT; the CD45hi KIT- differentiated MC (blue), CD45lo KIT+  EMP/myeloid progenitor (MP) (pink) 689 
and CD45- KIT+ populations (grey) were gated further for Csf1r-Egfp and tdTom.  690 
 691 
Extended data figure 4: Immunostaining controls for the analysis of cultured Csf1r-iCre-692 
targeted cells.  693 
The indicated cell populations were isolated by FACS from E12.5 Csf1r-iCre;RosatdTom livers or 694 
blood and cultured for three days in methocult before adherent cells were stained. In the first panel 695 
in each row, the phase contrast and DAPI images were merged. In panels 2-4 in each row, 696 
immunolabelled cells are visualised together with tdTom fluorescence, with single channels for the 697 
indicated markers shown separately in grey scale. In (a,b), adherent cells from tdTom+ liver MC (a) 698 
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and EMP/MP (b) cultures were stained for ERG and VEGFR2 (top panels) or with secondary 699 
antibodies only (bottom panels). In (c), adherent cells from tdTom+ blood EMP/MP cultures were 700 
immunostained for CSF1R together with the myeloid markers CD45 (top panels) or F4/80 (bottom 701 
panels). Symbols: Arrows indicate tdTom+ ECs, arrowheads tdTom+ myeloid cells. Solid and clear 702 
symbols indicate the presence or absence, respectively, of the indicated markers. Abbreviations: 703 
met, methocult; FN, fibronectin. Scale bars: 20 µm. 704 
 705 
Extended data figure 5: Csf1r-iCre-mediated Hoxa ablation impairs the EMP lineage.  706 
(a-f) Schematic representation of the Hoxa cluster and adjacent Evx1 gene, including position of 707 
the LoxP sites used for gene targeting. (b) FACS strategy to isolate KIT+ cells from control (pooled 708 
Csf1r-iCre- or Csf1r-iCre+;Hoxa+/+; n=14), Hoxa+/fl;Csf1r-iCre heterozygous (n=6) and E12.5 709 
Hoxafl/fl;Csf1r-iCre mutant livers (n = 8). (c) qPCR analysis of Hoxa gene copy number relative to 710 
Evx1. Data are shown as mean ± SD; each symbol represents the value for one individual liver; * P 711 
< 0.05, *** P < 0.001 (1-way ANOVA, Tukey’s multiple comparisons test). (d-f) Representative 712 
FACS analysis (d) and quantification (e,f) of liver cell populations at E12.5 shows a similar number 713 
of CD45+ or CD45+ CD11b+ cells (differentiated MCs) in control (pooled Csf1r-iCre- or Csf1r-714 
iCre+;Hoxa+/+, n=25 for CD45+ and n=17 for CD45+ CD11b+) versus  Hoxafl/fl;Csf1r-iCre (n=7 for 715 
CD45+ and n=6 for CD45+ CD11b+). Mean ± SD fold change in mutants compared to control; each 716 
data point represents the value for one hindbrain; ** P < 0.01; ns, non-significant (unpaired t-test).   717 
(g-i) E12.5 hindbrains of the indicated genotypes were immunolabelled to determine vascular 718 
complexity and microglia. (g) Schematic representation of embryonic hindbrain position (left) and 719 
location of the hindbrain areas i-iv used for quantification in each hindbrain (right); values for the 720 
four areas in each hindbrain were averaged to obtain the value for that hindbrain; EC 721 
quantifications are shown in Fig. 5c. (h) Confocal z-stacks after wholemount labelling with IB4 and 722 
for RFP to visualise tdTom and F4/80 to visualise microglia; the white boxes indicate areas shown 723 
in higher magnification in Fig. 5. (i) Quantification of microglia number in Hoxafl/fl;Csf1r-iCre 724 
mutants (n=9) versus controls (n=10, pooled Csf1r-iCre+;Hoxa+/+ and Csf1r-iCre- of any Hoxa 725 
genotype). Mean ± SD fold change in mutant compared to control hindbrain; each data point 726 
represents the value for one hindbrain; ** P < 0.01 (unpaired t-test).   727 
(j-l) Confocal z-stacks of E11.5 Csf1+/+ and Csf1+/op littermate hindbrains, wholemount labelled for 728 
F4/80 together with IB4 (j) before quantification of the number of microglia (k) and vascular 729 
branchpoints (l); note that a 50% microglia reduction in Csf1+/op compared to Csf1+/+ hindbrains did 730 
not reduce vascular complexity. Mean ± SD; each data point represents the value for one 731 
hindbrain, n=3 each; ** P < 0.01; ns, non-significant (unpaired t-test).   732 
Scale bars: 200 µm (h), 100 µm (j). 733 
 734 
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Extended data figure 6: Csf1r-iCre-targeted ECs proliferate in vivo. 735 
(a,b) Confocal z-stacks of E12.5 Csf1r-iCre;RosatdTom wholemount yolk sac (a) or hindbrain (b) 736 
after staining for the proliferation marker pHH3 and VEGFR2 or for pHH3 together with IB4, 737 
respectively, and shown together with tdTom fluorescence. The areas indicated with white squares 738 
are shown in higher magnification below the corresponding panel, with tdTom and pHH3 channels 739 
also shown separately in grey scale. Symbols: The arrows indicate proliferating tdTom+ pHH3+ 740 
ECs.  Solid and clear symbols indicate the presence or absence, respectively, of tdTom 741 
fluorescence. The wavy arrow indicates a tdTom- pHH3+ neural progenitor. Scale bars: 200 µm 742 
(top panels), 20 µm (lower panels). 743 
(c-e) Cell cycle distribution of tdTom+ and tdTom- ECs. (c) FACS gating strategy to isolate tdTom+ 744 
and tdTom- PECAM1+ cells from E12.5 Csf1r-iCre;RosatdTom embryos. (d) Graphic representation 745 
of cell distribution based on Hoechst 33342 fluorescence as a measure of DNA content; low and 746 
high staining intensity is observed in cells with a DNA ploidy of 2n, i.e. G0/G1 phase, or 4n, i.e. 747 
G2/M phase, respectively; an intermediate staining intensity corresponds to S phase. (e) 748 
Quantification of the proportion of tdTom+ and tdTom- PECAM1+ cells in the G1, S and G2/M 749 
phases based on the area of the corresponding peaks in (d). Mean ± SD, n = 3 each; n.s., non-750 
significant (paired t-test). 751 
 752 
Extended data figure 7: Validation of gene expression data from RNAseq and microarray 753 
studies.  754 
ECs were isolated by FACS as in Fig. 6a for validation of RNAseq and microarray data presented 755 
in Fig. 6d-f.  756 
(a) Relative transcript levels of the Rosa26 locus by RNAseq of E12.5 tdTom+ and tdTom- EC 757 
populations, whose analysis is presented in Fig. 6a-f; mean ± SD of normalised counts, n=3 each; 758 
** P < 0.01 (unpaired t-test).  759 
(b) RT-qPCR analysis for the indicated genes in tdTom+ versus tdTom- ECs isolated from the 760 
whole embryo (n=5) to validate differentially expressed genes identified via RNAseq in Fig. 6e,f.   761 
(c) RT-qPCR analysis for the indicated genes in tdTom- ECs isolated from the brain and liver (n=3 762 
each) to validate organ-specific transcript enrichment identified via microarray analysis in Fig. 6f. 763 
(d) RT-qPCR analysis for the indicated genes to directly compare the expression levels of brain 764 
and liver EC differentiation markers in tdTom+ versus tdTom- ECs isolated from brain (n=3) or liver 765 
(n=5) (d) at E12.5.  766 
Slc2a1 was analysed as a representative brain EC-enriched transcript/differentiation marker, Mrc1 767 
and Oit3 as representative liver EC-enriched transcripts. Mean ± SD of fold change; * P < 0.05, ** 768 
P < 0.01, *** P < 0.001; ns, non-significant (unpaired t-test); ND, not detectable. 769 
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Extended data figure 8: Csf1r-iCre-targeted ECs contribute to embryonic organ vasculature. 770 
(a) Cryosections of the indicated organs from E12.5 Csf1r-iCre;RosatdTom mice were 771 
immunolabelled for the indicated EC markers together with antibodies for RFP to identify tdTom 772 
protein (top and bottom panels) or are shown with tdTom fluorescence (middle panels); single 773 
channels are shown in grey scale. The white boxes indicate the position of areas shown in higher 774 
magnification in Fig. 6g; note that some areas selected for higher magnification are not contained 775 
entirely within the field of view, and accordingly the boxes are not complete. Scale bars: 200 µm. 776 
(b) Gating strategy for flow cytometry of dissociated cells from E12.5 Csf1r-iCre;RosatdTom embryos 777 
and a control sample lacking iCre after staining with antibodies for CD11b, CD41, CD45, KIT, 778 
PECAM1 to determine the relative contribution of tdTom+ versus tdTom- ECs to vasculature in the 779 
brain, lung, heart and liver (associated quantifications shown in Fig. 6i; an analogous strategy was 780 
used for the quantifications shown in Fig. 6j and in the Extended Data Fig. 9b). 781 
 782 
Extended data figure 9: Csf1r-iCre-targeted ECs contribute to organ vasculature in late 783 
stage embryos.  784 
(a) Cryosections of the indicated organs from E18.5 Csf1r-iCre;RosaYfp mice were immunolabelled 785 
for YFP, PECAM1 and the macrophage marker IBA1; single channels are shown in grey scale. 786 
Symbols: Arrowheads indicate YFP+ and IBA1+ macrophages; solid and empty arrows indicate ECs 787 
that are YFP+ and lack IBA1 expression, respectively. Scale bars: 20 µm. 788 
(b) Flow cytometry of dissociated cells from the indicated organs of E18.5 Csf1r-iCre;RosatdTom 789 
embryos after staining with antibodies for CD11b, CD41, CD45, KIT, PECAM1, using the gating 790 
strategy shown in the Extended data Fig. 8a; mean ± SD, n = 5 each; *** P > 0.001 (1-way 791 
ANOVA, Tukey’s multiple comparisons test). 792 
(c) Working model for the role of EMPs in generating extra-embryonic yolk sac and intra-793 
embryonic organ ECs alongside their known role in generating myeloid and 794 
erythrocyte/megakaryocyte cells. 795 
 796 
Extended data figure 10: Csf1r-iCre-targeted ECs contribute to adult organ vasculature. 797 
Cryosections of the indicated organs from 6 months old adult Csf1r-iCre;RosaYfp (a) or 3 months 798 
old adult Csf1r-iCre;RosatdTom (b) mice were immunolabelled for the indicated EC and macrophage 799 
markers together with antibodies for YFP or RFP; single channels are shown in grey scale. The 800 
white box in (b) indicates an area shown in higher magnification in Fig. 6h. Symbols: Arrowheads 801 
indicate YFP+ and F4/80+ macrophages; solid and empty arrows indicate ECs that are YFP+ and 802 
lack F4/80 expression, respectively. Scale bars: 20 µm (a), 100 µm (b). 803 






